Optibrium bolsters its global AI drug discovery software operations with three key appointments

Optibrium bolsters its global AI drug discovery software operations with three key appointments

Optibrium, a leading developer of artificial intelligence (AI) software and solutions for drug discovery, today announced three key appointments: Michelle Harrison as Head of Strategic Marketing, Chris Khoury as Associate Business Development Manager and Imran Ghauri as Business Development Manager.

These appointments bring broad expertise in AI and life sciences and will align business development and marketing strategies globally to further develop and commercialize the company’s computational drug discovery technologies.

Driven by recent investments and continued business growth, Optibrium plans to double its headcount by the end of 2023, including recruitment for management positions.

Michelle joins Optibrium as Head of Strategic Marketing with 8 years of marketing experience, delivering high-impact strategy and effective marketing campaigns for scale-ups in drug discovery and digital health to to successfully target global audiences in the pharmaceutical, biotechnology, academic and investor sectors.

Michelle was previously senior marketing manager at Healx, where she gained significant expertise in the area of ​​AI drug discovery, as well as messaging, brand and team culture.

Chris assumes the role of Associate Director of Business Development for KATAOKA-SS America, a manufacturer of laser technology specializing in cellular treatment for areas such as regenerative medicine and drug discovery research, with his prior experience focused on the development of life sciences at an early stage. businesses.

Chris has established a strong scientific foundation as a research scientist in analytical and protein biochemistry at The Fountain Group and in protocol development at PerkinElmer.

He holds an MS in Biochemistry from California State University and a BS in Biochemistry and Molecular Biology from Dalhousie University.

Imran takes on the role of Business Development Manager from Sensyne Health, where he supported global sales of the company’s AI-based clinical platform, providing life science and healthcare customers. insights into real-world data across multiple therapeutic areas.

Imran has over 30 years of experience in account management and business development, with a track record of success in acquiring and retaining customers in a number of market sectors.

These include big pharma, biotech, NHS primary and secondary care. He holds a BSc in Chemistry from Swansea University.

More than 170 organizations worldwide, including five of the world’s top ten pharmaceutical companies, are currently deploying Optibrium’s drug discovery computational technologies in their research programs.

Cerella, Optibrium’s proven AI platform, empowers project teams with valuable insights from complex drug discovery data to maximize the success of preclinical discovery projects.

I am a true believer in harnessing the latest technological advances to improve the drug discovery process. I look forward to working alongside the team at such an exciting stage of Optibrium’s growth to extend the reach and impact of their cutting-edge AI capabilities and ultimately help deliver more quickly effective treatments to people.

Michelle Harrison, Head of Strategic Marketing, Optibrium

As part of our continued expansion and commercial success, we are delighted to welcome Michelle, Chris and Imran to the Optibrium team. Their impressive experiences in scientific marketing strategy and business development will fuel the next phase of our development and further strengthen the position of our market leader in silico technologies and AI platforms.

Dr. Matthew Segall, CEO, Optibrium

Based in Cambridge, UK, Optibrium also has offices in Boston and San Francisco, USA.

#Optibrium #bolsters #global #drug #discovery #software #operations #key #appointments

Leave a Comment

Your email address will not be published. Required fields are marked *